Lenalidomide in Kaposi Disease Associated With HIV Infection

Inclusion Criteria: * Men or non childbearing (negative serum Human Chorionic Gonadotropin-hCG) non breastfeeding women who practice adequate birth control, maintained 4 weeks after stopping lenalidomide * Age over 18 years and below 75 years * Able and willing to give written informed consent * Serologic documentation of HIV infection by approved tests, undetectable HIV viral load (below 50 copies/mL) independently of CD4 cell counts * Biopsy proven symptomatic Kaposi sarcoma with at least 4 measurable cutaneous lesions * Treatment by cART for at least 12 months, without wash out the last 6 months with undetectable HIV-RNA (below 50 copies/mL) * History of treatment failure or relapse with 1 or more chemotherapy * Progressive disease with need to new specific therapy * Wash-out over 4 weeks if previous specific Kaposi sarcoma chemotherapy (8 weeks if Interferon -IFN therapy) * Karnofsky performance status over 70% * Social security (State Medical Assistance is not a social security scheme) * Agree to abstain from donating blood * Agree not to donate semen * Agree not to share study drug with another person Exclusion Criteria: * Childbearing or breastfeeding (positive betaHCG serum) * Kaposi sarcoma with only visceral locations * Kaposi sarcoma with cardiac and/or bronchopulmonary localisations * 2 viral loads over 50 copies/mL under Highly active antiretroviral therapy (HAART), during the last 6 months * Opportunistic infections, uncontrolled infections * Cardiac disease …